KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Operating Leases (2021 - 2025)

Ionis Pharmaceuticals (IONS) has 5 years of Operating Leases data on record, last reported at $262.7 million in Q3 2025.

  • For Q3 2025, Operating Leases rose 56.01% year-over-year to $262.7 million; the TTM value through Sep 2025 reached $262.7 million, up 56.01%, while the annual FY2024 figure was $161.8 million, 5.31% down from the prior year.
  • Operating Leases reached $262.7 million in Q3 2025 per IONS's latest filing, up from $164.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $262.7 million in Q3 2025 and bottomed at $19.4 million in Q4 2021.
  • Average Operating Leases over 5 years is $165.1 million, with a median of $168.7 million recorded in 2024.
  • Peak YoY movement for Operating Leases: soared 820.86% in 2022, then dropped 5.5% in 2025.
  • A 5-year view of Operating Leases shows it stood at $19.4 million in 2021, then skyrocketed by 820.86% to $178.9 million in 2022, then decreased by 4.51% to $170.9 million in 2023, then dropped by 5.31% to $161.8 million in 2024, then surged by 62.34% to $262.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $262.7 million in Q3 2025, $164.4 million in Q2 2025, and $159.4 million in Q1 2025.